Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Processa Pharmaceuticals, Inc. Director's Dealing 2022

Apr 4, 2022

35172_dirs_2022-04-04_cfe8baad-b400-4c88-a2fa-57cf8125b992.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-11-01

Reporting Person: Guy Wendy (Chief Administrative Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-11-01 Restricted Stock Units $0 A 4286 Acquired Common Stock (4286) Direct
2022-03-31 Restricted Stock Units $0 A 10715 Acquired Common Stock (10715) Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.